Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the
AMD is poised to become the second-largest customer of TSMC's 5nm process platform in the second half of 2022, as the CPU vendor will be ramping up 5nm wafer starts at the foundry, according to industry sources.